Alessia Levaggi
Overview
Explore the profile of Alessia Levaggi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raffa S, Lanfranchi F, Satragno C, Giannelli F, Marcenaro M, Coco A, et al.
Curr Probl Cancer
. 2023 Sep;
47(6):101007.
PMID: 37684197
The last version of the FIGO classification recommended imaging tools to complete the clinical assessment of patients with cervical cancer. However, the preferable imaging approach is still unclear. We aimed...
2.
Razeti M, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, et al.
Clin Breast Cancer
. 2023 Jan;
23(3):241-248.
PMID: 36710145
In patients with early breast cancer, the combination of different systemic treatment strategies, including chemotherapy, endocrine therapy, targeted therapy, and more recently also immunotherapy has demonstrated to significantly improve their...
3.
Miglietta F, Cinquini M, Dieci M, Cortesi L, Criscitiello C, Montemurro F, et al.
Breast
. 2022 Nov;
66:293-304.
PMID: 36379199
Background: Approximately 5-10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes. The poly-ADP ribose polymerase (PARP)-inhibitors olaparib and talazoparib have...
4.
Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, et al.
Cancer J
. 2022 May;
28(3):176-182.
PMID: 35594464
Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged...
5.
Conte B, Montemurro F, Levaggi A, Blondeaux E, Molinelli C, Cardinali B, et al.
Tumori
. 2022 Jan;
109(1):71-78.
PMID: 34989265
Objective: Neoadjuvant chemotherapy has become the preferred treatment in HER2-positive early breast cancer. Several trials investigated the neoadjuvant efficacy of dual HER2 blockade with anthracycline-free chemotherapy, whereas few data are...
6.
Parisi F, Razeti M, Blondeaux E, Arecco L, Perachino M, Tagliamento M, et al.
Clin Med Insights Oncol
. 2020 Jul;
14:1179554920931816.
PMID: 32647477
Breast cancer is the most frequent malignancy diagnosed in premenopausal women. In this age group, breast tumors tend to be diagnosed at more advanced stages and to harbor more aggressive...
7.
Blondeaux E, Lambertini M, Michelotti A, Conte B, Benasso M, Dellepiane C, et al.
Br J Cancer
. 2020 Apr;
122(11):1611-1617.
PMID: 32231293
Background: Adjuvant chemotherapy is the standard of care in high-risk early breast cancer patients. Dose-dense should be the preferred schedule of administration. However, its long-term benefit is unknown. Methods: In...
8.
Dieci M, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31398896
In the absence of identified therapeutic targets, chemotherapy is the main systemic treatment option for triple-negative breast cancer (TNBC). The achievement of a pathological complete response (pCR) after neoadjuvant chemotherapy...
9.
Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, et al.
Eur J Cancer
. 2018 Jun;
99:9-19.
PMID: 29886394
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include...
10.
Lambertini M, Anserini P, Fontana V, Poggio F, Iacono G, Abate A, et al.
BMC Cancer
. 2017 May;
17(1):346.
PMID: 28526012
Background: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing...